RGNT Stock Forecast: Regentis Biomaterials Ltd. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Regentis Biomaterials Ltd. hold a median 12-month price target of $10 — +434.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
RGNT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Regentis Biomaterials Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Volatility (2): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Regentis Biomaterials Ltd. — and when they’d sell — is the membership.
RGNT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RGNT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +434.8% from it.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RGNT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Regentis Biomaterials Ltd. (RGNT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.9×
- EV / EBITDA
- −0.2×
Cheaper than 47% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −288.6%
- Return on assets
- −107.5%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
RGNT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RGNT appears on the weeks it earns a place.
Frequently asked questions about RGNT stock
What is the RGNT stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Regentis Biomaterials Ltd. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RGNT stock a buy right now?
Of the 1 analysts covering Regentis Biomaterials Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Regentis Biomaterials Ltd. 14 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RGNT?
As at 1 Aug 2026, Regentis Biomaterials Ltd. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
Will RGNT stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +434.8% from the last close, and Ticker Nerd's factor model ranks Regentis Biomaterials Ltd. 14 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RGNT stock forecast for 2030?
No analyst covering Regentis Biomaterials Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
What does Regentis Biomaterials Ltd. do?
Regentis Biomaterials Ltd. is a healthcare company specializing in regenerative medicine, with a focus on orthopedic tissue repair solutions.
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. is a healthcare company specializing in regenerative medicine, with a focus on orthopedic tissue repair solutions. The company develops therapies designed to restore function in damaged or diseased cartilage and bone, targeting patients with painful joint conditions, particularly in the knee. Its core technology is the Gelrin platform, a degradable hydrogel implant engineered to support the regeneration of native tissue rather than simply replacing it. Gelrin is composed of polyethylene glycol diacrylate and denatured fibrinogen, forming a biocompatible matrix used in minimally invasive procedures. The company’s lead product, GelrinC, is a cell-free, off-the-shelf implant that is cured in situ within the knee to treat articular cartilage injuries. Operating within the medical instruments and supplies segment of the healthcare sector, Regentis Biomaterials serves orthopedic specialists and healthcare providers seeking advanced biomaterial-based solutions for joint preservation. Founded in 2004 and headquartered in Israel, it contributes to the growing market for regenerative orthopedic treatments.
CEO Dr. Ehud Geller Ph.D. · 3 employees · Israel · https://www.regentis.co.il